Racura Oncology (ASX:RAC) Cyclically Adjusted PS Ratio: (As of Jul. 07, 2026)

Racura Oncology  (ASX:RAC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Racura Oncology Cyclically Adjusted PS Ratio Related Terms

The historical data trend for Racura Oncology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Cyclically Adjusted PS Ratio Chart

Racura Oncology Annual Data
	Trend	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24	Jun25
Cyclically Adjusted PS Ratio		Get a 7-Day Free Trial					0.00	0.00	0.00	0.00	0.00

Racura Oncology Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ASX:RAC vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Racura Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Racura Oncology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Racura Oncology's Cyclically Adjusted PS Ratio falls into.

Racura Oncology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Racura Oncology's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jun25 is calculated as:

For example, Racura Oncology's adjusted Revenue per Share data for the fiscal year that ended in Jun25 was:

Current CPI (Jun25) = 131.5506.

Racura Oncology Annual Data

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Racura Oncology Business Description